Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data and AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma and Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
Subscribe
Subscribe

False

The Analytical Scientist / Issues / 2024 / Dec / Deep Profiles for Personalized Medicine
Omics Proteomics Clinical

Deep Profiles for Personalized Medicine

How small molecule enhancements revolutionize plasma proteomics

By Helen Bristow 12/19/2024 1 min read

Share

Researchers have demonstrated that adding small molecules to plasma can significantly expand the detection of low-abundance proteins, addressing a major challenge in plasma proteomics. The research, published in Nature Communications, reveals that small molecule-induced modulation of protein coronas on nanoparticles boosts proteome coverage, aiding biomarker discovery and disease monitoring.

Plasma proteomics often struggles with detecting low-abundance proteins because of the dominance of high-abundance ones like albumin, which comprise 85 percent of plasma protein mass. This study explored how small molecules, including phosphatidylcholine (PtdChos), glucose, and triglycerides, influence the protein corona – a layer of proteins adsorbed on nanoparticle surfaces. By modifying plasma samples with these molecules, researchers achieved an 8.25-fold increase in the number of proteins detected compared with plasma alone.

Using polystyrene nanoparticles, the team quantified 1,793 unique proteins through liquid chromatography-mass spectrometry (LC-MS/MS), far surpassing the 218 proteins detected in untreated plasma. Remarkably, PtdChos alone enabled the identification of 897 proteins, including low-abundance ones, by selectively reducing albumin and other high-abundance proteins in the corona.

The study also showed that the addition of PtdChos improved proteoform quantification by enriching proteins linked to diseases like cardiovascular and neurodegenerative disorders.

Molecular dynamics simulations further revealed that PtdChos interacts with albumin through hydrophobic interactions and hydrogen bonds, reducing its representation in the corona. This strategy eliminates the need for costly and labor-intensive albumin depletion kits, streamlining proteomics workflows.

The findings have broad implications for biomarker discovery and personalized medicine. By enabling deeper plasma proteome profiling, the approach could uncover novel biomarkers and improve early disease diagnosis. Future studies aim to validate the method across diverse patient cohorts, paving the way for its clinical adoption in precision diagnostics.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Helen Bristow

Combining my dual backgrounds in science and communications to bring you compelling content in your speciality.

More Articles by Helen Bristow

False

Advertisement

Recommended

False

Related Content

The Analytical Scientist Innovation Awards 2024: #7
Omics
The Analytical Scientist Innovation Awards 2024: #7

December 2, 2024

4 min read

Frank Steemers, co-founder and CSO of Scale Biosciences, tells us the story of ScalePlex – the 7th ranked innovation on this year’s Awards

The Analytical Scientist Innovation Awards 2024: #4
Omics
The Analytical Scientist Innovation Awards 2024: #4

December 5, 2024

6 min read

Thermo Fisher Scientific’s high-sensitivity mass spec for translational omics research – the Stellar MS – is ranked 4th in our annual Innovation Awards

Let Me See That Brain
Omics
Let Me See That Brain

December 9, 2024

1 min read

TRISCO sets a new standard for 3D RNA imaging, delivering high-resolution and uniform images to offer insights into brain function and anatomy

The Analytical Scientist Innovation Awards 2024
Omics
The Analytical Scientist Innovation Awards 2024

December 11, 2024

10 min read

Meet the products – and the experts – defining analytical innovation in 2024

False

The Analytical Scientist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.